Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study compared novel hormonal agents (NHAs) for non-metastatic castration-resistant prostate cancer (nmCRPC) in Taiwan. While treatment responses were similar, apalutamide showed more adverse events, and darolutamide had lower discontinuation rates.
Area Of Science
- Oncology
- Pharmacology
- Urology
Background
- Non-metastatic castration-resistant prostate cancer (nmCRPC) is a critical stage in prostate cancer progression.
- Novel hormonal agents (NHAs) are standard treatments for nmCRPC, improving survival.
- Evidence on NHA efficacy and safety in Asian populations requires further investigation.
Purpose Of The Study
- To compare the efficacy and safety of apalutamide, darolutamide, and enzalutamide in Taiwanese nmCRPC patients.
- To evaluate real-world treatment outcomes and adverse event profiles of NHAs.
- To identify potential differences in NHA performance within an Asian demographic.
Main Methods
- Retrospective analysis of 64 nmCRPC patients from two Taiwanese prostate care centers.
- Comparison of patient characteristics, prostate-specific antigen (PSA) responses, and adverse events.
- Statistical analysis of treatment efficacy and safety data.
Main Results
- Similar treatment responses were observed across apalutamide, darolutamide, and enzalutamide groups.
- Apalutamide was associated with a higher incidence of adverse events, particularly skin rash.
- Darolutamide demonstrated lower discontinuation rates due to adverse events compared to other NHAs.
Conclusions
- Real-world data on NHA utilization in Taiwanese nmCRPC patients offer valuable insights.
- Variations in adverse event profiles necessitate individualized treatment strategies.
- Regional considerations are crucial for optimizing nmCRPC treatment outcomes with NHAs.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
